SCHEMBL68751

SCHEMBL68751

CCCCCC#CCC#CCC#CCC#CCCCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 1.00
TDP1 Q9NUW8 4/20 1.00
ALDH1A1 P00352 3/20 1.00
RECQL P46063 2/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
KDM4E B2RXH2 1/20 1.00
USP2 O75604 1/20 1.00
POLB P06746 1/20 1.00
MAPT P10636 1/20 1.00
HPGD P15428 1/20 1.00
ALOX12 P18054 1/20 1.00
BLM P54132 1/20 1.00
MCL1 Q07820 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
HMGCR P04035 3/20 0.78
EPHX2 P34913 4/20 0.63
AKR1B1 P15121 1/20 0.58
PPARG P37231 4/20 0.56
PPARD Q03181 4/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10458468 1.00 PTPN7 (1.00) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL31189059 1.00 PTPN7 (1.00) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL10456798 1.00 PTPN7 (1.00) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL10458369 0.98 TDP1 (1.00) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL28742640 0.98 TDP1 (1.00) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL11071577 0.98 TDP1 (1.00) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL26624753 0.98 TDP1 (1.00) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL10919883 0.98 TDP1 (1.00) PTPN7TDP1ALDH1A1RECQLMEN1
SCHEMBL68425 0.98 TDP1 (1.00) PTPN7TDP1ALDH1A1RECQLMEN1
Hydrochloric Acid SCHEMBL9421484 0.96 TDP1 (0.96) PTPN7TDP1ALDH1A1RECQLMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 741 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4744663-A2 SKIN COMPOSITION Eaderm Co., Ltd. (JP) 2026-05-20 EP claimed
CN-118079006-A Skin composition 国立大学法人东京医科齿科大学 2024-05-28 CN claimed
US-20220331389-A1 SKIN COMPOSITION EADERM CO., LTD. (JP) 2022-10-20 US claimed
EP-3978020-A1 SKIN COMPOSITION National University Corporation Tokyo Medical and Dental University (JP) 2022-04-06 EP claimed
EP-3878947-A2 MATURATION OF MAMMALIAN HEPATOCYTES Takara Bio Europe AB (SE) 2021-09-15 EP claimed
US-20210189332-A1 MATURATION OF MAMMALIAN HEPATOCYTES TAKARA BIO EUROPE AB (SE) 2021-06-24 US claimed
US-10913932-B2 Maturation of mammalian hepatocytes TAKARA BIO EUROPE AB (SE) 2021-02-09 US claimed
US-20190024044-A1 MATURATION OF MAMMALIAN HEPATOCYTES TAKARA BIO EUROPE AB (SE) 2019-01-24 US claimed
US-10105455-B2 Fluorocoxib A loading into ROS-responsive nanoparticles VANDERBILT UNIVERSITY (US) 2018-10-23 US claimed
US-9945843-B2 Methods for identifying compounds that inhibit G protein-coupled receptor (GPR84) agonist-stimulated chemotaxis GALAPAGOS NV (BE) 2018-04-17 US claimed
US-6060515-A TOPICALLY APPLYING TO MAMMALIAN SKIN OR MUCOUS MEMBRANE A BARRIER DEVELOPMENT ENHANCING AMOUNT OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPARA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-05-09 US claimed
CN-1248916-A Use of FXR, PPAR 'alpha' and LXR 'alpha' activators to restore barrier function, promote epidermal differentiation and inhibit proliferation UNIV CALIFORNIA (US) 2000-03-29 CN claimed
US-6004987-A ANTIINFLAMMATORY AGENTS FOR MAMMALS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1999-12-21 US claimed
WO-1998032444-A1 USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-07-30 WO claimed
US-5760043-A USING 2-AMINOPYRIDINE-3-OXIDE L'OREAL (FR) 1998-06-02 US claimed
EP-0353123-B1 Ureic 2,4,6-triamino-pyrimidine-3-oxide derivatives, their preparation and their cosmetical and dermapharmaceutical use OREAL (FR) 1994-08-24 EP claimed
EP-0279954-B1 AMIDES OF EICOSATETRAYNOIC ACID, THEIR PHARMACEUTICAL AND COSMETIC USE, THEIR PREPARATION AND PROCESS FOR THE PREPARATION OF EICOSATETRAYNOIC ACID CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) 1993-03-17 EP claimed
US-5034387-A Applying to skins for hair growth and skin disorders L'OREAL (FR) 1991-07-23 US claimed
EP-0396251-A2 Use of fatty acids for the treatment of diseases associated with cytokines NATIONAL UNIVERSITY OF SINGAPORE (SG) 1990-11-07 EP claimed
US-4181725-A BROMOPHENACYL BROMIDE, TOCOPHEROL, MEPACRINE, (HYDROXY)CHLOROQUINE, DIBUCAINE, TETRACAINE, LIDOCAINE, BUTACAINE, PROCAINE, EDTA THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1980-01-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10105455-B2 Fluorocoxib A loading into ROS-responsive nanoparticles ROS1, CYBB, NOXO1 PTPN7 2112/4885TDP1 3282/4885ALDH1A1 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.